Eli Lilly swaps horseshoe crab blood for lab-made alternative, cutting deaths by 80%

For 40 years, pharmaceutical companies have relied on the blue blood of horseshoe crabs to detect endotoxins—dangerous bacterial contaminants—in vaccines, IV drips, dialysis fluids, and medical devices. The crabs' unique immune cells clot in the presence of these toxins, making their blood an irreplaceable safety net for injectable medicine. But this biomedical harvesting takes a toll: roughly 200,000 crabs are caught each year in Massachusetts alone, with a national total tripling over the last two decades. The Atlantic States Marine Fisheries Commission estimates about 15% of crabs die during bleeding. Additionally, horseshoe crab eggs feed migratory shorebirds, sharks, and turtles, so population declines ripple through coastal ecosystems.

Eli Lilly, a major pharmaceutical company, has been working on a solution. Scientists have created a lab-made version of the essential protein—recombinant Factor C—that reacts to endotoxins exactly like the natural crab blood does. After testing thousands of samples across hundreds of products, Eli Lilly confirmed the synthetic alternative performs as well or better. The company began the switch in 2016 and now handles 80% of its testing synthetically, with plans to phase out crab blood entirely. Massachusetts has also stepped in: 2023 brought a harvesting cap, and 2024 added a ban on all crab harvesting from April 15 to June 7, protecting 90% of the spawning season. Survey data shows 71% of state sites now report increasing crab populations, a sign that conservation efforts are working. As Eli Lilly's Jay Bolden puts it, with a proven synthetic alternative available, there's 'no excuse to use a wild animal' for these tests—a sentiment that may reshape the entire biomedical industry.